PTAB grants inter partes review of China’s firm’s Alzheimer’s patent

The US Patent Trial and Appeal Board (PTAB) has given the go-ahead for an inter partes review of a Chinese pharma company’s US patent related to a treatment for Alzheimer’s.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

From migraine drugs to COVID vaccine spats, US lawsuits pile up

9 January 2026 A busy week in US courts saw major pharma companies and biotech firms move to protect key therapies and research tools, with new lawsuits over migraine and cancer drug generics, and alleged misuse of COVID-19 vaccine tech.

Americas

Insulin pump rivals face off in major trade secrets dispute hearing

8 January 2026 Important questions about when companies must act on suspicions of theft and whether damages can stack with injunctions were raised in a dispute that has already sent ripples across med tech.

Americas

Bayer enters COVID-19 vaccine row with three suits against major drugmakers

8 January 2026 Crop science division alleges that vaccine developers used patented mRNA stability technology in shots that earned them around $140 billion in global sales.

More features

From migraine drugs to COVID vaccine spats, US lawsuits pile up

How AI will be shaped by legal and regulatory developments in 2026

Deadline extended: Who are the world’s best in-house counsel?

‘All voices must be heard’: New CIPA president sets out plans for 2026

Insulin pump rivals face off in major trade secrets dispute hearing

Bayer enters COVID-19 vaccine row with three suits against major drugmakers

Arnold & Porter loses another regulatory partner to growing rival

CIPA’s outgoing president: UK rejoining the UPC needs ‘support from business’

PTAB grants inter partes review of China’s firm’s Alzheimer’s patent

More on this story

Editor's picks

Editor's picks

More features